NCT00166413View on ClinicalTrials.gov

Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis

PHASE2CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

December 31, 2006

Conditions

Amyloidosis

Interventions

DRUG

CC-5013

40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER